Divalproex Sodium Tablet, Delayed Release
Product Images NDC 71335-2124

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71335-2124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 01)

Chemical structure of divalproex sodium showing a polymeric structure with sodium ions associated with carboxylate groups. The diagram includes the branched alkyl chains characteristic of the valproic acid derivative.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 02)

A bar chart comparing two studies showing percentage response rates for placebo (PBO) and Divalproex Sodium (DVPX). Study 1 (YMRS) shows 26% for placebo and 60% for Divalproex Sodium, while Study 2 (IMRS) shows 29% for placebo and 58% for Divalproex Sodium. Percentages are displayed on the vertical axis.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 03)

A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium and placebo. The vertical axis shows the percent reduction, ranging from -100% (worsening) to 100% (improvement), while the horizontal axis indicates the percentage of patients from 100% to 0%. Two lines represent the data: a solid line for Divalproex Sodium and a dotted line for placebo, illustrating their respective effects on CPS rate reduction.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 04)

A cumulative percent reduction graph showing improvement or worsening in CPS rate among patients taking Divalproex Sodium delayed-release tablets. The graph compares high-dose and low-dose groups, plotting percent reduction on the vertical axis against percent of patients on the horizontal axis.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 05)

A bar chart comparing two studies showing measurement values for Placebo versus Divalproex Sodium. The vertical axis represents a numeric scale, with Placebo bars higher than Divalproex Sodium bars in both studies. Study 1 and Study 2 sections each display two bars labeled Placebo and Divalproex Sodium respectively.*

FDA Label Image

Image (39cef9df 868d 4963 B0a7 7f146275442f 06)

FDA Label Image

Label (Lbl713352124)

Label for Divalproex Sodium 500 mg delayed release oral tablets by Bryant Ranch Prepack. The label notes comparison to Depakote 500 mg ER tablets and indicates a package size of 60 tablets. It includes storage instructions for room temperature and a reminder to keep the container tightly closed. The NDC number 71335-2124 is shown prominently.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.